Study S001941

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05680129
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 623
Start: 2023-01-10
Primary completion: 2024-07-03
Lead sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Conditions: T2DM; Type 2 Diabetes Mellitus
Interventions: DRUG:Ecnoglutide high dosage; DRUG:Ecnoglutide low dosage; DRUG:Dulaglutide; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in HbA1c [Baseline, week 32]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006211	Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. He Y, The lancet. Diabetes & endocrinology	2025	Randomized trial	PMID 40854315 DOI	cites ClinicalTrials.gov:NCT05680129; registry reference DERIVED:40854315